Literature DB >> 16088227

Age-related increase of kynurenic acid in human cerebrospinal fluid - IgG and beta2-microglobulin changes.

Berthold Kepplinger1, Halina Baran, Astrid Kainz, Heber Ferraz-Leite, Jea Newcombe, Pavol Kalina.   

Abstract

Kynurenic acid (KYNA) is an endogenous metabolite in the kynurenine pathway of tryptophan degradation and is an antagonist at the glycine site of the N-methyl-D-aspartate as well as at the alpha 7 nicotinic cholinergic receptors. In the brain tissue KYNA is synthesised from L-kynurenine by kynurenine aminotransferases (KAT) I and II. A host of immune mediators influence tryptophan degradation. In the present study, the levels of KYNA in cerebrospinal fluid (CSF) and serum in a group of human subjects aged between 25 and 74 years were determined by using a high performance liquid chromatography method. In CSF and serum KAT I and II activities were investigated by radioenzymatic assay, and the levels of beta(2)-microglobulin, a marker for cellular immune activation, were determined by ELISA. The correlations between neurochemical and biological parameters were evaluated. Two subject groups with significantly different ages, i.e. <50 years and >50 years, p < 0.001, showed statistically significantly different CSF KYNA levels, i.e. 2.84 +/- 0.16 fmol/microl vs. 4.09 +/- 0.14 fmol/microl, p < 0.001, respectively; but this difference was not seen in serum samples. Interestingly, KYNA is synthesised in CSF principally by KAT I and not KAT II, however no relationship was found between enzyme activity and ageing. A positive relationship between CSF KYNA levels and age of subjects indicates a 95% probability of elevated CSF KYNA with ageing (R = 0.6639, p = 0.0001). KYNA levels significantly correlated with IgG and beta(2)-microglobulin levels (R = 0.5244, p = 0.0049; R = 0.4253, p = 0.043, respectively). No correlation was found between other biological parameters in CSF or serum. In summary, a positive relationship between the CSF KYNA level and ageing was found, and the data would suggest age-dependent increase of kynurenine metabolism in the CNS. An enhancement of CSF IgG and beta(2)-microglobulin levels would suggest an activation of the immune system during ageing. Increased KYNA metabolism may be involved in the hypofunction of the glutamatergic and/or nicotinic cholinergic neurotransmission in the ageing CNS. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088227     DOI: 10.1159/000086295

Source DB:  PubMed          Journal:  Neurosignals        ISSN: 1424-862X


  28 in total

Review 1.  Involvement of kynurenines in Huntington's disease and stroke-induced brain damage.

Authors:  Trevor W Stone; Caroline M Forrest; Nicholas Stoy; L Gail Darlington
Journal:  J Neural Transm (Vienna)       Date:  2011-06-22       Impact factor: 3.575

2.  Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.

Authors:  Maria Holtze; Peter Saetre; Göran Engberg; Lilly Schwieler; Thomas Werge; Ole A Andreassen; Håkan Hall; Lars Terenius; Ingrid Agartz; Erik G Jönsson; Martin Schalling; Sophie Erhardt
Journal:  J Psychiatry Neurosci       Date:  2012-01       Impact factor: 6.186

Review 3.  Kynurenine Metabolism and Alzheimer's Disease: The Potential Targets and Approaches.

Authors:  Vivek Kumar Sharma; Thakur Gurjeet Singh; Nirbhay Kumar Prabhakar; Ashi Mannan
Journal:  Neurochem Res       Date:  2022-02-08       Impact factor: 3.996

4.  A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study.

Authors:  D Theofylaktopoulou; Ø Midttun; A Ulvik; P M Ueland; G S Tell; S E Vollset; O Nygård; S J P M Eussen
Journal:  Clin Exp Immunol       Date:  2013-07       Impact factor: 4.330

5.  Polymorphism of Kynurenine Pathway-Related Genes, Kynurenic Acid, and Psychopathological Symptoms in HIV.

Authors:  Vanessa Douet; Naomi Tanizaki; Adrian Franke; Xingnan Li; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-12       Impact factor: 4.147

6.  Elevated cerebrospinal fluid levels of beta-2-microglobulin in patients with Guillain-Barré syndrome and their correlations with clinical features.

Authors:  Ming-Qi Liu; Jing Wang; Chen-Na Huang; Yuan Qi; Lin-Jie Zhang; Ming Yi; Sheng-Hui Chang; Li-Sha Sun; Li Yang
Journal:  Neurol Sci       Date:  2021-02-17       Impact factor: 3.307

7.  Association of kynurenine aminotransferase II gene C401T polymorphism with immune response in patients with meningitis.

Authors:  Fladjule Rejane Soares de Souza; Fabrícia Lima Fontes; Thayse Azevedo da Silva; Leonam Gomes Coutinho; Stephen L Leib; Lucymara Fassarella Agnez-Lima
Journal:  BMC Med Genet       Date:  2011-04-07       Impact factor: 2.103

8.  Endogenous Kynurenine Aminotransferases Inhibitor is Proposed to Act as "Glia Depressing Factor" (GDF).

Authors:  Halina Baran; Berthold Kepplinger; Markus Draxler
Journal:  Int J Tryptophan Res       Date:  2010-05-11

9.  Understanding the roles of the kynurenine pathway in multiple sclerosis progression.

Authors:  Chai K Lim; Bruce J Brew; Gayathri Sundaram; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2010-08-25

10.  Kynurenic Acid Metabolism in Various Types of Brain Pathology in HIV-1 Infected Patients.

Authors:  H Baran; J A Hainfellner; B Kepplinger
Journal:  Int J Tryptophan Res       Date:  2012-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.